NX
NextCure, Inc.
NXTC · NASDAQ
$6.02 +2.56% (+$0.15)
1M +3.90%
Market Cap $21.7M
P/E Ratio -
Div. Yield -
ROE 175.46%
Bulios Fair Price
$6.89
14.5% upside
Current Price
$6.02
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NXTC is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
93 /100
Cheap P/B 1.79x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 40.70%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 259.91%
ROE 175.46%
ROA 188.98%
Debt
97 /100
Low Debt/Equity 0.35x
Current ratio 3.47x
Int. coverage N/A
Stability
61 /100
Moderate Beta 1.34x
EPS volatility 3.16%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NXTC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael S. Richman
Employees
40
Headquarters
Beltsville
Upcoming events
04 NOV
Earnings
Upcoming earnings report